AstraZeneca Paid US$100M for One Molecule. The Rest Trades at US$507M.

AstraZeneca had options. In late 2025, they chose to write a cheque for US$100 million (upfront, in cash) to acquire the rights to a single molecule from Jacobio Pharmaceuticals. The molecule is called JAB-23E73. It has not yet completed Phase I. Phase I is the first stage of human clinical trials, where researchers test basic safety and identify the right dose. AstraZeneca did not pay for Jacobio's approved drug. They did not pay for Jacobio's cash. They paid that sum for one early-stage compound.

At today's price of HK$7.22, the entire company costs approximately US$730 million to buy. After subtracting the HK$1.73 billion in cash already sitting in Jacobio's accounts, the market values everything that remains at US$507 million: one approved cancer drug on China's national reimbursement list, a Phase III clinical trial in progress, and the same pipeline AstraZeneca just wrote a nine-figure cheque to access.

The arithmetic deserves a second look.

What Jacobio Does

Jacobio Pharmaceuticals (1167.HK) is one of the few HKEX-listed biotechs focused on treating a genetic mutation found in certain lung cancers. Most people outside oncology have never heard of KRAS. When this gene mutates in a specific way, it acts like a stuck accelerator inside a cancer cell: it instructs the cell to keep growing and dividing when it should stop. One particular version is called KRAS G12C. It is found in roughly 8 to 10% of Chinese patients with non-small cell lung cancer. That is the most common form of the disease worldwide.

Jacobio's lead drug is called glecirasib. It is designed specifically to block that mutation. In simple terms, it is a molecule that fits into the KRAS G12C protein and turns off the stuck accelerator. It received formal approval from China's National Medical Products Administration in 2024. In late 2024 it was added to China's National Reimbursement Drug List (the NRDL).

That second step is the commercially significant one. Before NRDL inclusion, glecirasib could only reach patients willing and able to pay out of pocket. That is a small fraction of those who need it. After inclusion, the drug is funded by China's national healthcare system and can be prescribed to any eligible patient in any public hospital in the country. For a specialty drug, national formulary listing is effectively the starting gun for volume growth.

In parallel, Jacobio is running a Phase III clinical trial. This is the final stage of testing required before a drug can apply for an expanded treatment indication. This trial combines glecirasib with a class of drugs called PD-1 inhibitors. These drugs help the immune system recognise and attack cancer cells. The combination is being tested as a first-line treatment: patients who have not yet tried any other therapy. If successful, glecirasib would move from a second-line salvage setting to front-line standard of care, where the number of eligible patients is three to five times larger. Second-line drugs are prescribed only after other treatments have failed.

Why Jacobio Trades at a Discount

Two facts keep the share price where it is. Neither should be dismissed.

The first is the drug's early commercial numbers. Glecirasib was added to the NRDL in late 2024. The company had approximately seven months of nationally reimbursed sales before the end of the financial year. In those seven months, glecirasib generated RMB 8.55 million in revenue. That is roughly enough to treat 250 to 400 patients per month. In a country where the drug is theoretically eligible for tens of thousands of patients per year, that penetration rate is below 1%.

A growth curve that takes 18 to 24 months to build is being measured at month seven. Specialty oncology drugs in China routinely take 12 to 24 months after NRDL listing to reach meaningful volumes. Hospital formularies update on their own timetable. Physicians build experience. Patient flows ramp slowly. On that interpretation, the first seven months are simply too early to conclude anything. The same data point is also consistent with slower-than-expected adoption: hospitals delaying formulary activation, oncologists defaulting to more familiar treatments, or a patient pool smaller than the models assumed. Neither interpretation can be ruled out today.

The second fact is that KRAS G12C is less common in Chinese patients than in Western populations. The mutation appears in 8 to 10% of Chinese non-small cell lung cancer cases, compared to 13% in Western cohorts. The ceiling on glecirasib's addressable market in China is lower than early analysis suggested. The market has corrected for this.

The NRDL listing is seven months old. The ramp for specialty oncology drugs typically takes 18 to 24 months. The price at HK$7.22 is not waiting for that.

AstraZeneca's Cheque, Seven Months of Sales, Eleven Years of Cash

Each one changes what the residual value calculation produces. All three point in the same direction.

1. 01 AstraZeneca's payment is a data point, not a press release. Most pharmaceutical licensing deals are structured as milestone agreements: small amounts upfront, larger payments only as clinical results come in. AstraZeneca structured this deal differently: US$100 million in cash, paid before any pivotal trial data existed, for a molecule still in Phase I. AstraZeneca is one of the world's largest pharmaceutical companies. Its pipeline assessment processes are among the most rigorous in the industry. JAB-23E73 is what researchers call a pan-KRAS inhibitor: it targets a broader range of KRAS mutations than glecirasib does. A broader target means the potential to treat a much larger patient population. AstraZeneca also gains access to Jacobio's established commercial infrastructure in China. That infrastructure gives any new drug a faster path to patients than AstraZeneca could build from scratch. The US$1.9 billion in downstream milestone payments is the larger signal: AstraZeneca only pays those milestones if they actively choose to keep running trials and pursuing regulatory approvals globally. They would not have structured a deal this way without intending to pursue it.
2. 02 The NRDL listing is the starting gun, not the finish line. Drug launches in China follow a consistent pattern after national formulary inclusion. The first six to twelve months are typically slow: individual hospitals must add the drug to their own internal formularies, oncology teams must build clinical experience with the drug, and patients need to be identified and referred. The national listing opens the door. Each hospital walks through it on its own timetable. The seven months of sales through December 2025 represent the very beginning of a curve that typically takes 18 to 24 months to reach meaningful penetration. The first real read on whether adoption is accelerating will come when Jacobio publishes its H1 2026 interim results. Those results are expected around July or August 2026. Glecirasib's H1 2026 revenue resolves the most important open question in this thesis.
3. 03 Net cash of HK$1.73 billion gives Jacobio 11 years of runway. Jacobio is spending approximately RMB 146 million per year on research, clinical trials, and operations. At that burn rate, the cash balance provides eleven years of runway without any additional fundraising. This matters because the single largest risk for a pre-profit drug company is running out of money before the drug generates meaningful revenue. At Jacobio's current pace, that risk does not exist. The Phase III trial can be completed. New drug applications can be filed. In the worst-case scenario where glecirasib fails commercially and the Phase III halts, the company does not go to zero. The cash is the floor.

What Jacobio Is Actually Worth

Jacobio has no earnings. The standard way to value a company (measuring how many years of annual profit you are paying for) does not apply to a pre-profit drug developer. The method used instead is called a sum-of-parts valuation: each component of the business is valued separately, and the total is compared to the current market capitalisation.

Component one is the simplest. Jacobio holds HK$1.73 billion in net cash. That is approximately HK$2.20 per share across 787 million shares outstanding. This is money already in the bank. The figure is verifiable in the audited accounts. It requires no assumption and no forecast. It also defines the floor: a share price below HK$2.20 would mean investors are paying less than what the company holds in cash.

Component two is glecirasib. To value a commercial-stage drug, the approach is to estimate peak annual revenue (the highest sustainable sales level once the drug has reached full market penetration) and apply a multiple to that figure. At an NRDL-negotiated price of RMB 3 000–5 000 per patient per month and an eligible population of 80 000–120 000 patients per year in China, peak annual revenue is approximately RMB 200–350 million. A 5× price-to-sales multiple is conservative for a commercial-stage specialty oncology drug in China. Applied here, it produces approximately HK$1.25 billion of value.

Components three and four are probability-weighted. The Phase III combination trial is assigned a 30% probability of achieving first-line label approval. At that probability, it adds approximately HK$1.2 billion on a risk-adjusted basis. The AstraZeneca milestone payments are discounted at 35% probability of achieving major commercialisation thresholds. At that probability, they contribute approximately HK$1.6 billion. These numbers carry uncertainty. That is why a probability discount is applied. If that feels too optimistic, the cash component alone tells you the floor.

The base case is HK$7.60 per share. That barely moves from today's price. The bull case requires both catalysts: the commercial ramp and the Phase III trial. That combination targets HK$12–16. The bear case is the cash floor: HK$3–4. That reflects the cash value minus operating costs over the period it takes to wind down. The upside is multiple times the downside. That asymmetry is the structure of this situation.

Risks We Are Not Downplaying

Three risks are documented. None is hypothetical.

The Decision

Written at HK$7.22 on April 11, 2026.

This thesis has two moving parts. Both must be watched independently. Glecirasib's H1 2026 revenue either confirms that the commercial ramp is underway, or it doesn't. The Phase III combination trial either expands the drug's label from a second-line treatment to a first-line standard of care, or it doesn't. One without the other produces an outcome near today's price. Both together push the stock considerably higher. The cash floor holds the downside.

Three signals would invalidate the thesis outright: H1 2026 drug revenue below RMB 10 million; AstraZeneca deprioritising JAB-23E73 or acquiring a superior pan-KRAS asset externally; or a Phase III halt for futility. None of these has appeared. The pipeline has not failed. AstraZeneca's cheque has not bounced.

---